Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price objective cut by stock analysts at Scotiabank from $3.15 to $1.40 in a report issued on Friday,Benzinga reports. The brokerage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback